Uxin shares drop 45% as predicted by InvestingPro’s Fair Value model
Director Stelios Papadopoulos of EXELIXIS, INC. (NASDAQ:EXEL) sold 100,000 shares of common stock on November 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $43.55, with prices ranging from $43.55 to $43.58, resulting in a total transaction value of $4.35 million. The transaction occurred near the stock’s current trading price of $42.35, with Exelixis showing a P/E ratio of 18 and trading below its InvestingPro Fair Value.
Following the transaction, Papadopoulos directly owns 1,189,228 shares of Exelixis. This number includes 9,812 shares of Exelixis, Inc. common stock that will be issued to Papadopoulos upon vesting of restricted stock units.The sale comes as Exelixis maintains an "Excellent" financial health rating with a market cap of $11.38 billion. Despite this director’s sale, InvestingPro data shows management has been aggressively buying back shares, and the company has delivered a 27.18% year-to-date return. Access the comprehensive Pro Research Report on Exelixis and 1,400+ other stocks through InvestingPro.
In other recent news, Exelixis reported its third-quarter financial results for 2025, showing strong performance. The company achieved total revenue of $597.8 million, surpassing both Oppenheimer’s estimate of $584.0 million and the consensus forecast of $590.2 million. Additionally, Exelixis reported earnings per share (EPS) of $0.78, exceeding the forecasted $0.69. Despite these positive financial results, Oppenheimer has maintained its Perform rating on Exelixis, with a price target of $36.00. This suggests a neutral stance on the company’s stock performance. The revenue and earnings figures indicate robust financial health for the quarter. These developments reflect Exelixis’ ability to outperform market expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.